Aion Therapeutic Stock Operating Margin
| ANTCF Stock | USD 0.01 0 84.21% |
Aion Therapeutic fundamentals help investors to digest information that contributes to Aion Therapeutic's financial success or failures. It also enables traders to predict the movement of Aion Pink Sheet. The fundamental analysis module provides a way to measure Aion Therapeutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aion Therapeutic pink sheet.
Aion |
Aion Therapeutic Company Operating Margin Analysis
Aion Therapeutic's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Aion Therapeutic has an Operating Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
| All Next | Launch Module |
Aion Fundamentals
| Return On Equity | -4.17 | |||
| Return On Asset | -0.96 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 147.3 M | |||
| Shares Owned By Insiders | 17.68 % | |||
| Price To Book | 5.77 X | |||
| Gross Profit | (1.5 K) | |||
| EBITDA | (3.68 M) | |||
| Net Income | (3.82 M) | |||
| Cash And Equivalents | 1.85 K | |||
| Total Debt | 643.8 K | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 0.15 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (1.35 M) | |||
| Earnings Per Share | (0.04) X | |||
| Beta | 0.29 | |||
| Market Capitalization | 1.47 M | |||
| Total Asset | 150.14 K | |||
| Z Score | -78.0 | |||
| Net Asset | 150.14 K |
About Aion Therapeutic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aion Therapeutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aion Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aion Therapeutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Aion Pink Sheet
Aion Therapeutic financial ratios help investors to determine whether Aion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aion with respect to the benefits of owning Aion Therapeutic security.